Published in Ann Hematol on May 20, 2017
The measurement of observer agreement for categorical data. Biometrics (1977) 216.56
Intraclass correlations: uses in assessing rater reliability. Psychol Bull (1979) 71.07
Revised international prognostic scoring system for myelodysplastic syndromes. Blood (2012) 8.12
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood (2016) 4.94
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood (2013) 2.97
Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leuk Res (2007) 2.97
Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol (2012) 2.92
Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica (2008) 2.69
Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes. Haematologica (2006) 1.48
Inter-observer variance with the diagnosis of myelodysplastic syndromes (MDS) following the 2008 WHO classification. Ann Hematol (2012) 1.28
Myelodysplastic syndromes: diagnosis, prognosis, and treatment. Dtsch Arztebl Int (2013) 1.21
Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res (2000) 1.14
The WHO classification of MDS does make a difference. Blood (2003) 1.13
World Health Organization classification of the acute leukemias and myelodysplastic syndrome. Int J Hematol (2000) 1.12
Evaluation of dysplasia through detailed cytomorphology in 3156 patients from the Düsseldorf Registry on myelodysplastic syndromes. Leuk Res (2012) 0.98
Morphological classification of the myelodysplastic syndromes: how much more education of diagnosticians is necessary? Haematologica (2013) 0.97
Interobserver variance in myelodysplastic syndromes with less than 5 % bone marrow blasts: unilineage vs. multilineage dysplasia and reproducibility of the threshold of 2 % blasts. Ann Hematol (2014) 0.89
Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry. Br J Haematol (2015) 0.88
Multiparameter flow cytometry is instrumental to distinguish myelodysplastic syndromes from non-neoplastic cytopenias. Eur J Cancer (2015) 0.82
Implementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromes. Haematologica (2016) 0.81
Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group. Haematologica (2016) 0.79
Inter-observer agreement in myelodysplastic syndromes. Haematologica (2013) 0.78
Cellularity, characteristics of hematopoietic parameters and prognosis in myelodysplastic syndromes. Eur J Haematol (2015) 0.76
Proposal for refining the definition of dysgranulopoiesis in acute myeloid leukemia and myelodysplastic syndromes. Leuk Res (2013) 1.42
Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry. Br J Haematol (2015) 0.88
Ibrutinib is a safe and effective therapy for systemic mantle cell lymphoma with central nervous system involvement - a multi-centre case series from the United Kingdom. Br J Haematol (2016) 0.79
Anemia in the elderly: clinical implications and new therapeutic concepts. Haematologica (2014) 0.79
Quality control initiative on the evaluation of the dysmegakaryopoiesis in myeloid neoplasms: Difficulties in the assessment of dysplasia. Leuk Res (2016) 0.76
CD274 (PD-L1)/PDCD1 (PD-1) expression in de novo and transformed diffuse large B-cell lymphoma. Br J Haematol (2016) 0.75
Labile plasma iron levels predict survival in patients with lower-risk Myelodysplastic syndromes. Haematologica (2017) 0.75